NEW YORK, Aug. 13 (GenomeWeb News) - Lynx Therapeutics reported that it has signed a non-binding letter of intent to merge with the privately held, UK-based company Solexa. Solexa will provide Lynx with up to $2.5 million in loans to sustain Lynx's operations.

 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers suggest that genetic variations could influence the side effects people experience when using synthetic cannabinoids, the International Business Times reports.

An analysis has examined the makeup of researchers on Twitter and what they share, Nature News reports.

At Stat News, Jim Kozubek argues that the Broad Institute is pushing the boundary of what a nonprofit is.

In PNAS this week: gut microbes may affect honeybee weight, phenotype and gene expression changes in DiGeorge syndrome, and more.